NobleBlocks

Research indexJournal article

治疗总效应作为精神分裂症长期治疗评估标准的局限性

施慎逊

Chin J Psychiatry5 Jun 2014

NobleIDark:/48914/w1/20260515/22FEEF3EDOI10.3760/cma.j.issn.1006-7884.2014.03.016

Paywalled

The full text is at the publisher

You can read the abstract here, or open it at the publisher.

Read at the publisher

Abstract

自从干预治疗抗精神病药的临床试验 (Clinical Antipsychotic Trials of Intervention Effectiveness,CATIE) 研究发表后,治疗总效应(effectiveness)这个专用名词逐渐为大家熟悉。CATIE研究的目的:比较第2代抗精神病药与第1代抗精神病药——奋乃静的治疗总效应的差异,比较第2代抗精神病药(如奥氮平、利培酮、奎硫平和齐拉西酮)之间的治疗总效应的差异。在CATIE研究中,评估治疗总效应的主要指标是任何原因的停止治疗率(rate of the discontinuation of treatment for any cause,RDT),并通过任何原因停药前的持续服药时间(time to treatment discontinuation,TTD)。次要指标是停止治疗的特殊理由(specific reasons for discontinuation of treatment,SRDT)[1]。

Discussion

Topics

More

Suggest a correction or report